Genomic Sequencing in Anatomically Normal Fetuses
Part of paid clinical trials in San Francisco, California.
- Sponsor
- University of California, San Francisco
- Study ID
- NCT06211348
- Status
- Recruiting
Conditions
- Pregnant Individuals Requesting Standard Microarray
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 64 Years
- Healthy Volunteers
- Accepted
Interventions
- Genomic Sequencing — DEVICEIndividuals who request prenatal diagnostic testing with standard chromosomal microarray will be offered genomic sequencing (GS) as an option to assess for additional disease risk.
Study Details
This cohort study will examine the clinical utility of genomic sequencing (GS) in patients undergoing prenatal diagnostic procedures (chorionic villus sampling or amniocentesis) for routine indications other than a structural fetal anomaly.
Key Dates
- Start date
- Jan 1, 2024
- Status verified
- Apr 2026
- Primary completion
- Jan 31, 2029
- Completion
- Jan 31, 2030
Study Design
- Enrollment
- 1,000 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- DIAGNOSTIC
Arms
- Experimental: Genomic Sequencing
Primary Outcome Measure
Detection of pathogenic or likely pathogenic variants with genomic sequencing [ Time Frame: Up to 2 months after enrollment ]
Central Contacts
- Nuriye Sahin Hodoglugil, DrPH415-353-3400
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of California, San Francisco | San Francisco | California | 94143 | Nuriye Sahin Hodoglugil, DrPH Mary Norton, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in San Francisco, CA
By research site